Evolutionary Genomics Inc (FNAM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access FNAM Annual Balance Sheets →
Tracking balance sheet results across Evolutionary Genomics Inc to Dec 31 2021 helps illustrate how Dec 31 2022's financial position has responded to changing business conditions.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2022)
(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent0.58
Cash & Short-term Investments0.00
Other Current Assets0.08
Prepaid Expense, Current AS0.04
Total Current Assets0.70
Equipment/Property/Plant Net0.00
Intangible Assets1.65
Income Taxes Receivable PR0.08
Other Assets, Noncurrent0.00
Total Assets2.35
Liabilities
Accounts Payable and Accrued Liabilities, Current LI0.18
Dividends Payable, Current IN1.84
Other Liabilities, Current0.00
Total Current Liabilities2.01
Long-term debt3.74
Total Long-term Debt3.74
Other liabilities, Noncurrent0.18
Total Liabilities3.92
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock12.38
Retained Earnings / Accumulated Deficit-19.81
Other Equity-2.19
Common Stockholder's Equity-9.62
Preferred Stockholder's Equity0.00
Non-controlling interests & other4.02
Total Stockholder's Equity-5.59
Liabilities & Stockholder's Equity2.35
4 historic quarters locked

Sign in to unlock the full Evolutionary Genomics Inc balance sheet history.

About Evolutionary Genomics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001553350-23-000160

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.